Focused Lung Treatment to Reduce Right Heart Strain
Résumé de l'étude
Pulmonary embolism (PE) is a blood clot that blocks and stops blood flow to an artery in the lung. Patients with PE may experience shortness of breath, chest pain, and/or an irregular heartbeat. The symptoms arise due to abnormal heart function. PE can be fatal, but prompt treatment significantly reduces the risk of death. With this clinical study, we hope to gather data on the safety and efficacy of the Vertex Pulmonary Embolectomy System in patients with acute PE. Up to 145 patients will be enrolled in the study. All participating patients will receive treatment with the investigational product. The Vertex Pulmonary Embolectomy System is a medical device intended for use in the pulmonary arteries for: • The non-surgical removal of blood clots from blood vessels. • The injection, infusion, and/or aspiration of contrast agents and other fluids into or out of a blood vessel. The general procedures in this study include inserting a catheter into a large vein in the leg to bring the medical device into the arteries of the lung that contain the blood clots, removing the clots, administering blood-thinning medications, imaging of the heart and lungs, blood tests, and other routine blood tests. The total study duration is approximately 30 days and includes the initial screening examination, hospitalization with the procedure performed, discharge from the hospital, and a follow-up visit 30 days after the procedure.
(BASEC)
Intervention étudiée
Patients with clinical signs and symptoms of blood clots in the lung and heart who meet the study criteria will be treated with the Vertex Pulmonary Embolectomy System. In this study, we will investigate the safety and efficacy of the Vertex Pulmonary Embolectomy System in patients who exhibit clinical signs and symptoms of blood clots in the lung that have formed suddenly within the last 14 days. Up to one hundred twenty-three (123) evaluable subjects will be treated in this study.
(BASEC)
Maladie en cours d'investigation
Acute Pulmonary Embolism Investigating the safety and efficacy of the new medical device Vertex Pulmonary Embolectomy System for the mechanical aspiration of clots in the treatment of acute pulmonary embolism (PE).
(BASEC)
1. Acute onset of symptoms < 14 days indicating pulmonary embolism. 2. RV/LV ratio of > 0.9 on CTA as assessed by the investigator (determined by the study center). 3. Systolic blood pressure ≥ 90 mmHg (the initial systolic blood pressure may be ≥ 80 mmHg if the pressure recovers with fluids to ≥ 90 mmHg) (BASEC)
Critères d'exclusion
1. Use of thrombolytics within 30 days of baseline CT angiography (CTA) 2. Pulmonary hypertension with peak pressure in the pulmonary artery > 70 mmHg by right heart catheterization (determined by the study center) 3. Vasopressor required after fluids to maintain pressure at ≥ 90 mmHg (BASEC)
Lieu de l’étude
Bâle
(BASEC)
Sponsor
The Sponsor: Neptune Medical Inc. The Sponsor's Representative: Effectum Medical AG
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Karlee Hunter
+1 7072914074
karlee@clutterneptunemedical.comNeptune Medical Inc.
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
20.05.2025
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II. The SPIRARE II Study (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible